Phase I and II clinical trial design for targeted agents.
- Published in:
- Targeted Oncology, 2006, v. 1, n. 4, p. 220, doi. 10.1007/s11523-006-0030-5
- By:
- Publication type:
- Article
Works matching IS 17762596 AND DT 2006 AND VI 1 AND IP 4
Results: 8
1
2
The clinical challenge of imatinib resistance in chronic myeloid leukemia: emerging strategies with new targeted agents.
- Published in:
- Targeted Oncology, 2006, v. 1, n. 4, p. 186, doi. 10.1007/s11523-006-0032-3
- By:
- Publication type:
- Article
3
Apoptosis: mechanisms and implications for cancer therapeutics.
- Published in:
- Targeted Oncology, 2006, v. 1, n. 4, p. 197, doi. 10.1007/s11523-006-0034-1
- By:
- Publication type:
- Article
4
Any drug that works has a target.
- Published in:
- 2006
- By:
- Publication type:
- Editorial
5
ErbB4 expression in squamous cell carcinoma of the head and neck.
- Published in:
- Targeted Oncology, 2006, v. 1, n. 4, p. 181, doi. 10.1007/s11523-006-0029-y
- By:
- Publication type:
- Article
6
VEGF as a target.
- Published in:
- Targeted Oncology, 2006, v. 1, n. 4, p. 239, doi. 10.1007/s11523-006-0027-0
- By:
- Publication type:
- Article
7
Breast cancer clinical practice recommendations from Saint-Paul-de-Vence: excerpts concerning targeted therapies.
- Published in:
- Targeted Oncology, 2006, v. 1, n. 4, p. 228, doi. 10.1007/s11523-006-0033-2
- By:
- Publication type:
- Article
8
Angiogenesis and antiangiogenic treatment in lung cancer.
- Published in:
- Targeted Oncology, 2006, v. 1, n. 4, p. 215, doi. 10.1007/s11523-006-0031-4
- By:
- Publication type:
- Article